(Q43046800)

12 November 2017

title

Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. (English)

1 reference

12 November 2017

1 reference

1 reference

S Knapp

1

1 reference

12 November 2017

L J Yee

2

1 reference

12 November 2017

A J Frodsham

3

1 reference

12 November 2017

B J W Hennig

4

1 reference

12 November 2017

S Hellier

5

1 reference

12 November 2017

L Zhang

6

1 reference

12 November 2017

M Wright

7

1 reference

12 November 2017

M Chiaramonte

8

1 reference

12 November 2017

M Graves

9

1 reference

12 November 2017

H C Thomas

10

1 reference

12 November 2017

A V S Hill

11

1 reference

12 November 2017

M R Thursz

12

1 reference

12 November 2017

publication date

1 September 2003

1 reference

12 November 2017

1 reference

12 November 2017

volume

4

1 reference

12 November 2017

issue

6

1 reference

12 November 2017

page(s)

411-419

1 reference

Inhibition of human parainfluenza virus-3 replication by interferon and human MxA.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

The 2-5A system in viral infection and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Interferons and their actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Adenovirus inhibition of cellular protein synthesis involves inactivation of cap-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

A mechanism for the control of protein synthesis by adenovirus VA RNAI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

PKR--a protein kinase regulated by double-stranded RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Isolation of the interferon-inducible RNA-dependent protein kinase Pkr promoter and identification of a novel DNA element within the 5'-flanking region of human and mouse Pkr genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Genomic features of human PKR: alternative splicing and a polymorphic CGG repeat in the 5'-untranslated region

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Activity of the interferon-induced 2',5'-oligoadenylate synthetase in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Protective effects of the sickle cell gene against malaria morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Heterozygote advantage for HLA class-II type in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

No adjustments are needed for multiple comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

Interferon-induced proteins and the antiviral state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

7 January 2021

Human MxA protein confers resistance to Semliki Forest virus and inhibits the amplification of a Semliki Forest virus-based replicon in the absence of viral structural proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

7 January 2021

Human MxA protein protects mice lacking a functional alpha/beta interferon system against La crosse virus and other lethal viral infections

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

7 January 2021

Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

7 January 2021

2′,5′ oligoadenyIate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GENE.6363984

7 January 2021

Identifiers

DOI

10.1038/SJ.GENE.6363984

1 reference

12 November 2017

1 reference